CN1274338C - Traditional Chinese medicine for treating aplastic anemia and its preparation process - Google Patents
Traditional Chinese medicine for treating aplastic anemia and its preparation process Download PDFInfo
- Publication number
- CN1274338C CN1274338C CNB031254667A CN03125466A CN1274338C CN 1274338 C CN1274338 C CN 1274338C CN B031254667 A CNB031254667 A CN B031254667A CN 03125466 A CN03125466 A CN 03125466A CN 1274338 C CN1274338 C CN 1274338C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- aplastic anemia
- treatment
- traditional chinese
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000032467 Aplastic anaemia Diseases 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 239000007779 soft material Substances 0.000 claims abstract description 10
- 241001446509 Psoralea Species 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920001353 Dextrin Polymers 0.000 claims abstract description 4
- 239000004375 Dextrin Substances 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 235000019425 dextrin Nutrition 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 70
- 241000208340 Araliaceae Species 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 241000545442 Radix Species 0.000 claims description 8
- 210000000582 semen Anatomy 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000010410 dusting Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 239000000843 powder Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010065553 Bone marrow failure Diseases 0.000 abstract description 2
- 206010033661 Pancytopenia Diseases 0.000 abstract description 2
- 208000009527 Refractory anemia Diseases 0.000 abstract description 2
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 abstract description 2
- 208000024389 cytopenia Diseases 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 235000011837 pasties Nutrition 0.000 abstract 3
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000209020 Cornus Species 0.000 abstract 1
- 240000007371 Cuscuta campestris Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000011132 hemopoiesis Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 13
- 230000002607 hemopoietic effect Effects 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102000015696 Interleukins Human genes 0.000 description 10
- 108010063738 Interleukins Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 210000002960 bfu-e Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 5
- 229960000912 stanozolol Drugs 0.000 description 5
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- -1 SIL-2R Proteins 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 206010003883 azoospermia Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000008634 oligospermia Diseases 0.000 description 2
- 230000036616 oligospermia Effects 0.000 description 2
- 231100000528 oligospermia Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000010028 chemical finishing Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses traditional Chinese medicine for curing aplastic anemia and a preparation technology thereof. The traditional Chinese medicine is a medicament proportionally prepared from red ginseng tails, astragalus root, prepared rehmannia root, dodder seed, sliced cornus cervi, broil tortoise plastron, fructus lycii, psoralea fruit, cooked aconite and cassia bark. In the preparation technology of the present invention, the 10 kinds of traditional Chinese medicine raw materials are decocted for two times by being added with water, and filter solutions obtained through the two time decoction are combined; then, the filter solutions are concentrated, deposited by ethanol and refrigerated to a room temperature for becoming a pasty object; then, after being dried, the pasty object is sprayed with powder and is filled in a capsule for becoming a capsule preparation, or the pasty object is added with dextrin or starch for being prepared into a soft material; finally, the soft material is processed through sieving and drying for being prepared into powder preparation for infusion or being pressed into a tablet. The traditional Chinese medicine can regulate disturbance mediated by the immunity of human bodies, stimulate the restoration of the hematopoiesis function of the marrow of human bodies, and has an obvious effect on the cure of aplastic anemia. The traditional Chinese medicine has a good curative effect on symptoms, such as bone marrow depression, cytopenia, etc., caused by other refractory anemia and various reasons. Simultaneously, the traditional Chinese medicine nearly has no toxic or side effect, is safe and reliable, and has low cost.
Description
Technical field
The present invention relates to the Chinese herbal medicine is the kidney tonifying marrow facilitating medicament that feedstock production forms, and refers to a kind of Chinese medicine and preparation technology thereof who treats aplastic anemia particularly.
Background technology
Aplastic anemia has become very harmful blood system common disease as the hyperfunction disease of the secondary regulation and control of a kind of hemopoietic.They are many clinically based on chronic, protracted course of disease, and the treatment difficulty is high, does not still have ideal medicine so far, makes the clinicist quite feel thorny.Particularly in recent years along with the appearance of national house decoration upsurge, people are increasing with the probability that harmful chemical finishing material contacts, cause the sickness rate of China's aplastic anemia to increase year by year, and the trend that the patient becomes younger has appearred, therefore press for a kind of safe and reliable treatment new drug.
Domestic and international at present treatment to aplastic anemia, nothing more than following a few class medicine is arranged: one, androgen and cyclosporin are when for treating the most frequently used medicine of aplastic anemia now, but the two all has toxic and side effects in various degree, makes its clinical practice be subjected to very big restriction.Its two, cytokines such as GM-CSF, EPO, IL-3 begin to be used for aplastic anemia treatment in recent years, but its curative effect is not lasting, and cost an arm and a leg, be not the choice drug of treatment.They are three years old, Chinese patent drugs for treatment aplastic anemia, as promoting hemogenesis for aplastic anemia tablet common on the market, SHENGXUE WAN, FUFANG ZAOFAN WAN etc., but this type of Chinese patent medicine mainly has been the effect of YIN nourishing, pathogenic fire reducing, spleen reinforcing, the effect of benefit marrow hemopoietic is then relatively poor, so it can only improve patient's clinical symptoms mostly, clinical therapeutic efficacy is then not good enough, effective percentage only is 30～50%, and the patient still has to rely on Western medicine such as cyclosporin.
Summary of the invention
Purpose of the present invention will overcome above-mentioned the deficiencies in the prior art part exactly, and the Chinese medicine and the preparation technology thereof of a kind of safe and reliable, determined curative effect and treatment aplastic anemia with low cost is provided.By the kidney tonifying marrow facilitating Chinese medicine that this prepared forms, not only can regulate the immune-mediated disorder of human body, stimulate the recovery of human bone marrow's hemopoietic function, treatment aplastic anemia effect is remarkable, and does not almost have obvious toxic-side effects.
For achieving the above object, the present invention thinks according to China's theory of Chinese medical science and practice: the key of aplastic anemia morbidity is to suffer from a deficiency of the kidney, its essence is insufficiency of kidney-YANG, and with the effect of the useful marrow hemopoietic of the kidney invigorating ruling by law treatment aplastic anemia, its clinical effect is better than spleen reinforcing class and the clear Chinese medicine of growing class greatly.YIN-deficiency type aplastic anemia is converted into deficiency of yang type aplastic anemia, clinically just can alleviate.According to above-mentioned theory of Chinese medical science, with reference to modern pharmacological research, the present invention is from China's medicine treasure-house, filter out invigorating primordial QI, mend marrow, fill blood, the natural Chinese medicine of spleen reinforcing kidney, the body resistance strengthening and constitution consolidating, by the theory of Chinese medical science prescription, extract elite wherein, make its performance adjust immune-mediated disorder, releasing is to the inhibition of bone marrow hematogenesis, improve the level of IL-3, promote the propagation and the differentiation of hematopoietic stem, promote the endocrine hormone receptor affinity, and then the recovery of hemopoietic function, splendid to the chronic aplastic anemia effect.
The Chinese medicine of treatment aplastic anemia proposed by the invention is the medicament that is prepared from by following materials of weight proportions:
Leptoradix Ginseng Rubra 15～50 Radixs Astragali 5～30 Radix Rehmanniae Preparata 5～30
Semen Cuscutae 5～30 Cornu Cervi tablets 5～30 Carapax Et Plastrum Testudinis (processed) 5～30
Fructus Lycii 5～30 Fructus Psoraleaes 5～30 Radix Aconiti Lateralis Preparata 3～20
Cortex Cinnamomi 1～15.
The preferred weight proportioning of the raw material of preparation medicament of the present invention is:
Leptoradix Ginseng Rubra 20～40 Radixs Astragali 8～15 Radix Rehmanniae Preparata 8～15
Semen Cuscutae 8～15 Cornu Cervi tablets 8～15 Carapax Et Plastrum Testudinis (processed) 8～15
Fructus Lycii 8～15 Fructus Psoraleaes 8～15 Radix Aconiti Lateralis Preparata 5～10
Cortex Cinnamomi 1～8.
The optimum weight proportioning of the raw material of preparation medicament of the present invention is:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
Medicament of the present invention can be a said dosage form on any pharmaceutics, and what select for use usually is electuary, tablet or capsule.
The preparation technology of the Chinese medicine of treatment aplastic anemia of the present invention is: by above-mentioned weight proportion Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice, the decocting that at every turn adds 6～8 times of raw material weights boiled 30～60 minutes, merged filtrate twice.Concentrate then, precipitate with ethanol, be cooled to room temperature and become paste.Again paste is carried out dried, the fill of dusting after the adding appropriate amount of auxiliary materials becomes capsule.Or the dextrin or the starch that add 1～2 times of its weight in paste makes soft material, at last soft material sieved, drying, makes electuary or is pressed into tablet.
Basic research works such as clinical, the pharmacology of treatment aplastic anemia Chinese medicine of the present invention, toxicity, pharmacy are summarized as follows:
Completed clinical research is provided with two groups of identical matched groups of condition, and the result proves: basic healing, remission rate and the total effective rate of Chinese medicine preparation treatment group of the present invention all obviously is better than Western medicine " stanozolol " matched group.Observe the CD of kidney yang deficiency syndrome Patients with Aplastic Anemia simultaneously
3, CD
4/ CD
8Obviously reduce CD
8Obviously raise T
3, T
4, T, F significantly reduce, IL-2, IFN-γ, TNF-α significantly increase, sIL-2R, IL-3 obviously reduce, the essence of prompting kidney yang deficiency syndrome aplastic anemia is unbalance relevant with nerve--endocrine---immune system function.Kidney tonifying marrow facilitating Chinese medicine preparation of the present invention can be adjusted immune-mediated disorder on the one hand, improves CD
3, CD
4/ CD
8Ratio, reduce CD
8Quantity and activity, to remove the inhibition of disease to bone marrow hematogenesis.Can improve the sIL-2R level on the other hand, reduce the release of hemopoietic negative regulatory factors such as IL-2, IFN-γ, TNF-α.Can improve simultaneously the level of IL-3,, hemopoietic function of bone marrow be recovered to promote the propagation and the differentiation of hematopoietic stem.Experimentation shows: kidney tonifying marrow facilitating Chinese medicine preparation of the present invention can promote the growth of polytropism hemopoietic chief cell (CFU-S), red owner's cell (BFU-E) and grain owner's cell (CFU-C).Endocrine hormone especially androgen and hemopoietic has substantial connection, the metabolic endocrine hormone level of kidney yang deficiency syndrome aplastic anemia reflection function is obviously low, and after treatment by Chinese herbs of the present invention, can significantly go up, illustrate that this kidney tonifying marrow facilitating Chinese medicine preparation has the effect that promotes the hormone in vivo receptor affinity, helps the recovery of hemopoietic function.
Acute toxicological experiment records the LD of Chinese medicine preparation of the present invention
50＞190.75g/kg.It can improve the productive rate of immune-mediated property Induced Aplastic Anemia Mice bone marrow CFU-E, BFU-E, CFU-GM, CFU-Mix colony, points out its propagation to myeloid element, differentiation that facilitation is arranged; It can obviously improve the immunologic derangement of Induced Aplastic Anemia Mice, and its effect link is many-sided, and is different with immunosuppressant cyclosporin commonly used, and do not have the common toxic and side effects of immunosuppressant.
The invention has the advantages that: selecting ten crude drugs for use is that raw material carries out assembly, particularly this three flavors principal agent of Leptoradix Ginseng Rubra wherein, the Radix Astragali and Radix Rehmanniae Preparata merges utilization, QI invigorating, the kidney invigorating, the problem of enriching blood in the aplastic anemia treatment have been solved well, has the kidney warming benefit marrow, the unique effects of qi-supplementing, blood-engendering.The asthenia that can cure mainly the patient is deficient, oligospermia anemia, pallor is impractical, the empty fear of body is cold, have a dizzy spell, diseases such as the acid of waist knee joint is cold, cardiopalmus is weak, sexual impotence oligospermia, anorexia and loose stool.Confirm that through clinical observation its curative effect height, adaptability are strong, the total effective rate of treatment aplastic anemia obviously is better than existing Western medicine and similar Chinese medicine compound preparation, prescription up to 80%.And selected natural material does not have rare animal medical material, avirulence or limiting the use of property medical material, no valuable medicinal, the outer medical material of no grade III Standard, and each component meets the pharmaceutical control law regulation.Its co-action for treating aplastic anemia that organically combines, almost without any side effects.Simultaneously prepared and Chinese medicine need not to decoct, take with easy to carry, with low cost, greatly reduce total medical expense of patient, be easy to clinical application, have the wide development prospect.
In order to show the therapeutic effect of Chinese medicine of the present invention to aplastic anemia, the present invention is by the 4th criterion of therapeutical effect that national aplastic anemia academic conference is formulated in 1987, from being in hospital and blood special outpatient clinic selection case.Finished the collection of 80 routine clinical cases, random packet is observed, and wherein test group 50 examples are treated with Chinese medicine electuary of the present invention, and contrast I organizes 15 examples and treats with FUFANG ZAOFAN WAN, and contrast II group is treated with stanozolol.Test group 50 examples, male 31 examples, women 19 examples, 16～72 years old age, average 43.2 years old; Press the standard of Camitfa, aplastic anaemia 8 examples (comprising acute SAAI type 2 examples, chronic heavy type SAAI type 6 examples) wherein, chronic plain edition aplastic anemia 42 examples; The course of disease 3～42 months, average 19.6 months; Just control 22 examples, control 28 examples again.Contrast I organizes 15 examples (comprising SAAI type 4 examples), male 10 examples, women 5 examples, 21～68 years old age, average 39.6 years old; Contrast II organizes 15 examples (comprising SAAI type 4 examples), male 9 examples, women 6 examples, 18～69 years old age, average 41.8 years old.Three groups of patients are in aplastic anemia typing (heavy, plain edition) ratio, age, sex, the course of disease, control and reflect that all there is comparability (P＞0.05) aspects such as hemogram, bone marrow smear of state of an illness weight just, again.
Test group patient all takes Chinese medicine electuary of the present invention (entrusting the hospital preparation chamber to make electuary), and dosage: the adult takes 2 bags at every turn, and every bag 12 grams service once sooner or later.Contrast I group patient all takes FUFANG ZAOFAN WAN (its army's pharmacy company limited of Shaanxi Hao is produced), and dosage: the adult takes 9 at every turn, and every 1.8 gram is obeyed three every day.Contrast II group patient all takes stanozolol (Nanning Pharmaceutical Engerprise's production), dosage: the adult takes 2 milligrams at every turn, obeys every day three times.Treatment was a course of treatment with six months all.
Observation index: routine blood test adopts COULTERT-540 cytoanalyze electric-resistivity method to measure.The t lymphocyte subset group changes the employing indirect immunofluorescence and measures.Serum trilute (T
3), thyroxine (T
4), testosterone (T), hydrocortisone (F) changes uses measured by radioimmunoassay, presses the operation of test kit description method.Interleukin II (IL-2), soluble il-2 receptors (sIL-2R), interleukin (IL-3), r-interferon (IFN-r), the variation of a-tumor necrosis factor (TNF-a) all adopts the ELISA method to measure, and the strict test kit description method of pressing is operated.
Clinical test results is shown in table 1, table 2, table 3, table 4, table 5, table 6.
The clinical efficacy that table 1 is taken behind Chinese medicine of the present invention and compound recipe soap sulfone ball and the stanozolol compares
| Case load | Basic cure (%) | Alleviate (%) | Obviously progressive (%) | Invalid (%) | Total effective rate | |
| Test group contrasts 1 group and contrasts 2 groups | 50 15 15 | 4 examples (8%) 0 example, 0 example | 13 examples (26%) 2 example (13.33%) 2 example (13.33%) | 23 examples (46%) 4 example (26.67%) 5 example (33.33%) | 10 examples (20%) 9 example (60%) 8 example (53.33%) | 80％ 40％ 46.67％ |
As can be seen from Table 1, test group is cured substantially, alleviation and total effective rate all obviously be better than contrasting I group and contrast II group (P＜0.05 or P＞0.01).
The T cell subsets changes relatively before and after three groups of patient treatments of table 2
| Grouping | CD4(％) | CD4(％) | CD8(％) | CD4/CD8(％) | |
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 64.2±6.8 54.2±6.6 62.9±7.1 51.1±7.7 57.4±8.2 56.3±6.8 58.1±8.1 | 40.2±5.1 37.6±4.2 41.3±5.3 37.4±5.2 36.8±6.4 36.9±6.1 37.4±7.6 | 25.2±4.5 31.6±8.3 25.4±3.9 30.9±7.6 30.6±7.9 29.6±8.8 30.1±6.8 | 1.80±0.44 1.28±0.38 1.79±0.42 1.21±0.32 1.20±0.41 1.25±0.29 1.24±0.25 |
As can be seen from Table 2, the variation of three groups of treatment front and back T cell subsets.CD before the test group treatment
4And CD
4/ CD
8Than the obvious reduction of normal value (P＜0.05 or P＜0.01), obvious rising is arranged after the treatment, approach normal value, with comparing difference before the treatment significance (P＜0.05 or P＜0.01) is arranged, and CD
8Cell has obvious rising (P＜0.05) than normal value before treatment.T cell subsets data and test group comparing difference that contrast I group and contrast II group patient measure before treatment are infinitely added to the fun, and also do not have significant change after the treatment.Test group treatment back CD
4And CD
4/ CD
8Obviously rise CD
8Obviously descend, point out Chinese medicine electuary of the present invention, remove CD by regulating body's immunity
8Cell suppresses hemopoietic, helps hemopoietic and recovers.
The variation comparison of T3, T4, F and T before and after three groups of patient treatments of table 3 (X ± S)
| Grouping | T3 (ng/ml) | T4 (ng/ml) | F (ng/ml) | T(ng/ml) | ||
| The man | The woman | |||||
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 1.4±0.5 0.92±0.22 1.42±0.54 0.88±0.46 0.92±0.54 0.91±0.48 0.96±0.58 | 85±40 57±28 92±36 60±38 64±42 59±32 62±34 | 120±80 39±21 52±17 42±24 40±28 41±19 42±26 | 6.7±4 1.8±0.81 4.1±2.11 2.1±1.01 2.4±1.13 1.9±0.93 3.9±1.85 | 0.46±0.4 0.21±0.11 0.39±0.21 0.23±0.15 0.26±0.18 0.25±0.17 0.41±0.23 |
As can be seen from Table 3, three groups of patients serum T before treatment
3, T
4, T, F content all be lower than normal value.After treatment, test group patients serum T
3, T
4, T, F content all than the treatment before remarkable rising is arranged, difference has significance (P＜0.05); The level of T has remarkable rising behind the contrast II group patient treatment, and comparing difference with test group has significance (P＜0.05), may with androgen stimulate relevant, T
3, T
4, no significant change before and after the F treatment; Contrast I has no significant change before and after organizing every index treatment.
Table 4 three groups of patient IL-2, SIL-2R, IL-3, IFN-r, TNF-a change relatively
| Grouping | IL-2 | sIL-2R | IL-3 | IFN-r | TNF-a | |
| The normal value test group contrasts 1 group and contrasts 2 groups | After preceding treatment is treated in the treatment back before treating after the treatment before the treatment | 56.48±20.22 97.87±17.13 62.82±14.02 93.46±19.22 89.14±18.96 98.96±20.14 92.16±18.34 | 250±15 173.69±21.24 214.45±32.69 171.47±25.29 180.19±30.57 179.46±31.44 185.16±29.32 | 24.82±7.42 6.24±3.66 10.52±3.82 7.01±3.15 7.69±4.01 6.84±3.16 7.86±4.12 | 5.12±2.72 9.53±2.39 7.25±2.30 8.86±3.12 8.88±2.96 9.24±2.44 8.96±3.02 | 6.32±2.84 12.79±3.75 9.4l±2.97 12.18±4.12 11.98±4.38 13.14±3.96 12.82±3.46 |
As can be seen from Table 4, three groups of patients IL-2, IFN-r, TNF-a before treatment are significantly higher than normal value (P＜0.05), also are higher than normal value after the treatment; Significantly be lower than normal value (P＜0.01) before sIL-2R, the IL-3 treatment, also be lower than normal value after the treatment.But the IL-2 behind the test group 50 routine patient treatments, IFN-γ, TNF-a have remarkable reduction (P＜0.05) before the treatment, have obviously before sIL-2R, IL-3 treat and increase (P＜0.01), no significant change before and after contrast I group and contrast II group are treated.
Bone marrow BFU-E productive rate (individual/10 before and after three groups of patient treatments of table 5
5Variation BMMNC) (X ± S)
| Group | BFU-E | ||
| Before the treatment | After the treatment | ||
| Test group contrasts 1 group and contrasts 2 groups | 3.8±2.9 4.1±3.2 3.9±3.1 | The responder | The nonresponder |
| 23.9±20.3 12.4±11.7 13.6±12.8 | 6.2±4.6 6.1±5.2 5.8±4.9 | ||
Bone marrow cfu-gm productive rate (individual/10 before and after three groups of patient treatments of table 6
5Variation BMMNC) (X ± S)
| Group | CFU-GM | ||
| Before the treatment | After the treatment | ||
| Test group contrasts 1 group and contrasts 2 groups | 5.1±2.8 4.9±2.5 5.2±3.4 | The responder | The nonresponder |
| 18.2±22.1 7.8±4.4 8.2±12.8 | 4.6+2.9 4.8+3.0 3.9±23.6 | ||
From table 5, table 6 as can be seen, compare with normal value, bone marrow BFU-E and CFU-GM colony productive rate all significantly reduce (P＜0.01) before three groups of patient treatments, compare between these three groups, have comparability (P＞0.05).Treatment back test group responder's BFU-E colony productive rate is apparently higher than contrast I group and contrast II group (P＜0.05), and near normal value (P＞0.05); Test group responder CFU-GM colony productive rate is apparently higher than contrast I group and contrast II group (P＜0.01), but still be starkly lower than normal value (P＜0.05), this differs greatly relevantly with its different stage curative effect patient CFU-GM colony productive rate, does not obtain obvious curative effects person's (comprising obvious progressive person) bone marrow cfu-gm colony productive rate and recovers bad or seriously bad.Before three groups of nonresponder's bone marrow BFU-E and CFU-GM colony productive rates and the treatment relatively, no significant difference (P＜0.05).
All done inspections such as liver, renal function and electrocardiogram before and after three groups of patient treatments, clothes stanozolol person often has ALT to raise, decrement and add hepatoprotective after, ALT recovers normally gradually, other indexs all do not have change.With Chinese medicine electuary of the present invention and FUFANG ZAOFAN WAN therapist, all no abnormal change of liver, renal function and Electrocardioscopy illustrates that Chinese medicine electuary of the present invention has no side effect.
The specific embodiment
The Chinese medicine and the preparation technology thereof of treatment aplastic anemia of the present invention are described in further detail below in conjunction with specific embodiment:
Embodiment 1: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
Embodiment 2: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 30 Radixs Astragali 9 Radix Rehmanniae Preparata 9
Semen Cuscutae 9 Cornu Cervi tablets 9 Carapax Et Plastrum Testudinis (processed) 9
Fructus Lycii 9 Fructus Psoraleaes 9 Radix Aconiti Lateralis Preparata 9
Cortex Cinnamomi 3.
Embodiment 3: take by weighing raw material (kilogram) by following weight proportion:
Leptoradix Ginseng Rubra 35 Radixs Astragali 12 Radix Rehmanniae Preparata 12
Semen Cuscutae 11 Cornu Cervi tablets 11 Carapax Et Plastrum Testudinis (processed) 11
Fructus Lycii 10 Fructus Psoraleaes 14 Radix Aconiti Lateralis Preparata 9
Cortex Cinnamomi 5.
Its preparation technology is as follows: by the weight proportion in the foregoing description Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice, the decocting that at every turn adds 7 times of raw material weights boiled 45 minutes, merged the filtrate of twice decoction.Then the filtrate that merges is concentrated into relative density and is 1.15 (temperature 90 ℃ time measure), adding ethanol, to contain the alcohol amount to the filtrate be 55%, and precipitate with ethanol reclaimed ethanol more than 24 hours, further concentrated filtrate to relative density is 1.24 (temperature 90 ℃ time measure), is cooled to room temperature and becomes paste.
Again above-mentioned paste is carried out drying and sterilization place 30 minutes under 100～110 ℃ temperature, dust and make loose powder.Add an amount of adjuvant, but fill becomes capsule.Or the dextrin that adds 2 times of its weight in above-mentioned paste makes soft material, this soft material crossed behind 10 mesh sieves dry under 70 ℃ temperature, takes out, and granulate promptly can be made into dissolved granule after 12 mesh sieves.Or the starch that adds 1 times of its weight in above-mentioned paste makes soft material, this soft material crossed behind 10 mesh sieves dry under 70 ℃ temperature, takes out, and tabletting promptly can be made into tablet.
Patients with Aplastic Anemia can be taken this product according to the dose size of doctor's advice.In general, for the dissolved granule of every bag 10 grams, adult's secondary every day, each two bags, the morning and evening warm boiled water, six months is a course of treatment.Diseases such as the bone marrow depression that causes for other refractory anemia and a variety of causes, cytopenia, this product also has goodish curative effect.
Claims (5)
1. Chinese medicine for the treatment of aplastic anemia, it is characterized in that: it is the medicament that is prepared from by following materials of weight proportions:
Leptoradix Ginseng Rubra 25～35 Radixs Astragali 8～15 Radix Rehmanniae Preparata 8～15
Semen Cuscutae 8～15 Cornu Cervi tablets 8～15 Carapax Et Plastrum Testudinis (processed) 8～15
Fructus Lycii 8～15 Fructus Psoraleaes 8～15 Radix Aconiti Lateralis Preparata 8～9
Cortex Cinnamomi 2～5.
2. the Chinese medicine of treatment aplastic anemia according to claim 1 is characterized in that: the weight proportion of said each raw material is:
Leptoradix Ginseng Rubra 25 Radixs Astragali 8 Radix Rehmanniae Preparata 8
Semen Cuscutae 8 Cornu Cervi tablets 8 Carapax Et Plastrum Testudinis (processed) 8
Fructus Lycii 8 Fructus Psoraleaes 8 Radix Aconiti Lateralis Preparata 8
Cortex Cinnamomi 2.
3. the Chinese medicine of treatment aplastic anemia according to claim 1 and 2 is characterized in that: said medicament is a said dosage form on any pharmaceutics.
4. the Chinese medicine of treatment aplastic anemia according to claim 3 is characterized in that: said medicament is electuary, tablet or capsule.
5. the preparation technology of the Chinese medicine of the described treatment aplastic anemia of claim 4, it is characterized in that: Leptoradix Ginseng Rubra, the Radix Astragali, Radix Rehmanniae Preparata, Semen Cuscutae, Cornu Cervi tablet, Carapax Et Plastrum Testudinis (processed), Fructus Lycii, Fructus Psoraleae, Radix Aconiti Lateralis Preparata, ten raw material of Chinese medicine of Cortex Cinnamomi are decocted with water twice by above-mentioned weight proportion, the decocting that at every turn adds 6～8 times of raw material weights boiled 30～60 minutes, merged filtrate twice; Concentrate then, precipitate with ethanol, be cooled to room temperature and become paste; Again the fill of dusting after the paste dried is become capsule, or the dextrin or the starch that add 1～2 times of its weight in paste makes soft material, at last soft material is sieved, drying, make electuary or be pressed into tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031254667A CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031254667A CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1602896A CN1602896A (en) | 2005-04-06 |
| CN1274338C true CN1274338C (en) | 2006-09-13 |
Family
ID=34658755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031254667A Expired - Fee Related CN1274338C (en) | 2003-09-29 | 2003-09-29 | Traditional Chinese medicine for treating aplastic anemia and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1274338C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101401905B (en) * | 2008-11-10 | 2011-01-26 | 陈燕 | Chinese medicinal composition for treating aplastic anemia |
| CN105726776A (en) * | 2016-03-03 | 2016-07-06 | 郑州大学 | Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy |
| CN107751491A (en) * | 2016-08-19 | 2018-03-06 | 张金莲 | Health protection tea, preparation method and the usage |
-
2003
- 2003-09-29 CN CNB031254667A patent/CN1274338C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1602896A (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1256133C (en) | Antifatigue Chinese medicine composition and its prepn process | |
| CN1294015A (en) | Medicine for treating thyroid enlargement and thyroidism | |
| CN1370585A (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN1274338C (en) | Traditional Chinese medicine for treating aplastic anemia and its preparation process | |
| CN102274417B (en) | Chinese prepared medicament for treating aplastic anemia | |
| CN1202847C (en) | Diabetes treating medicine | |
| CN1158091C (en) | Chinese medicine composition for treating lung cancer | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1269493C (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1256963C (en) | Antifatigue medicine and its preparation method | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN1428166A (en) | Chinese medicine composition for curing AIDS and its preparation mehtod | |
| CN1097333A (en) | A kind of pure plant health preparation glycolipid disappears and method for making | |
| CN1562163A (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN1064249C (en) | Traditional Chinese medicine for indication nearsight | |
| CN1830477A (en) | Medicine for treating woman deficiency of blood gynecological and its preparation method | |
| CN1140292C (en) | Medicine for increasing leucocyte and its preparation | |
| CN1210049C (en) | Chinese medicine composition for treating diabetes | |
| CN1088801A (en) | Chinese patent medicine Jinguanpian tablets and the method for making thereof of treatment insensitive impediment, particularly RA and AS | |
| CN1840049A (en) | Medicine for treating diabetic nephropathy | |
| CN102988635A (en) | Nifedipine-containing medicinal composition | |
| CN101049344A (en) | Pharmaceutical composition of Qishen in use for treating leucopenia, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060913 Termination date: 20170929 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |